Skip to main content
logo
Ambu A/S (CPH:AMBU.B)
Denmark flag Denmark · Delayed Price · Currency is DKK
85.90
+1.85 (2.20%)
Feb 6, 2026, 10:20 AM CET

Revenue

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
Respiratory Revenue
1.83B1.82B
Urology (URO), Ear-Nose-Throat (ENT), and Gastroenterology (GI) Revenue
1.89B1.83B
Endoscopy Solutions Revenue
3.72B3.64B
Anesthesia Revenue
1.23B1.25B
Patient Monitoring Revenue
1.14B1.14B
Anesthesia and Patient Monitoring Revenue
2.37B2.39B

Revenue by Geography

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
North America Revenue
3.06B3.05B
Europe Revenue
2.46B2.41B
Rest of World Revenue
568.00M581.00M

Key Performance Indicators

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
Respiratory - Organic Revenue Growth
11.40%
Urology (URO), Ear-Nose-Throat (ENT), and Gastroenterology (GI) - Organic Revenue Growth
19.60%
Endoscopy Solutions - Organic Revenue Growth
15.40%
Anesthesia - Organic Revenue Growth
9.60%
Patient Monitoring - Organic Revenue Growth
10.20%
Anesthesia and Patient Monitoring - Organic Revenue Growth
9.90%
Total Organic Revenue Growth
13.10%
North America - Organic Revenue Growth
13.80%
Europe - Organic Revenue Growth
13.30%
Rest of World - Organic Revenue Growth
9.20%
Updated Dec 31, 2025. Data Source: Fiscal.ai.